Company / Shareholders' Equity
Tandem Diabetes Care Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$155.2M
FY2025
5-year range
$155.2M / $366.3M
FY2021-FY2025
Trend
-41.0%
vs FY2024
Sector context
#141 of 161
Health Care
What the data says
Tandem Diabetes Care's shareholders' equity of $155M is lower than 88% of companies in the Health Care sector (FY2025). Shareholders' Equity has declined for 3 consecutive years, from $366M in FY2022 to $155M in FY2025.
Based on SEC 10-K filings.
$155M in FY2025 with a 5-year CAGR of +3.4%.
Declined from $314M to $155M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -24.9%
- 5-Year CAGR
- +3.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 161This company $155.2M Sector average $5.1B
▼
-96.9% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +3.4%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 41.0% year-over-year.
- Ranks #141 out of 161 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $155.2M | -41.0% |
| FY2024 | $263.1M | -16.1% |
| FY2023 | $313.6M | -14.4% |
| FY2022 | $366.3M | +87.9% |
| FY2021 | $195.0M | +48.5% |
| FY2020 | $131.3M | +550.4% |
| FY2019 | -$29.1M | -391.8% |
| FY2018 | -$5.9M | -109.3% |
| FY2017 | $63.5M | +1170.8% |
| FY2016 | -$5.9M | -109.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026